61
Participants
Start Date
January 31, 2010
Primary Completion Date
June 6, 2022
Study Completion Date
June 6, 2022
Lenalidomide
Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
Placebo
Placebo, oral use, daily during study treatment (104 weeks)
Hospital Universitario Reina Sofía, Córdoba
Instituto Catalán de Oncología de Gerona, Girona
Hospital Infanta Leonor, Madrid
Hospital Clínico San Carlos, Madrid
Hospital Universitario La Paz, Madrid
Hospital General Universitario José Maria Morales Meseguer, Murcia
Centre Hospitalier Universitaire de Nîmes, Nîmes
Hospital Central de Asturias, Oviedo
Hospital de Cabueñes, Gijón
Hospital Clínico Universitario de Salamanca, Salamanca
Marien Hospital Duesseldorf, Düsseldorf
Hospital Universitario Virgen del Rocío, Seville
Centre Hospitalier Régional d'Orléans, Orléans
Hospital Universitario La Fe, Valencia
Hospital de Cruces, Barakaldo
Centre Hospitalier Universitaire d'Angers, Angers
Centre Hospitalier Universitaire Brabois, Nancy
Hôpitaux Universitaires de Strasbourg, Strasbourg
Hôspital St. Louis, Paris
Klinikum rechts der Isar der Technischen Universität München, München
Centre Hospitalier d'Avignon, Avignon
Universitaetsklinikum Carl Gustav Carus der Technischen Universitaet Dresden, Dresden
Hospital Son Llàtzer, Palma de Mallorca
Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona
Hospital Clínic i Provincial, Barcelona
Collaborators (1)
Celgene Corporation
INDUSTRY
Fundación General de la Universidad de Salamanca
OTHER